Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 31, 2017 07:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Announces September Conference Participation

INDIANAPOLIS, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
July 28, 2017 16:30 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

INDIANAPOLIS, July 28, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
May 26, 2017 07:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Announces June Conference Presentations

INDIANAPOLIS, May 26, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
February 21, 2017 07:05 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Announces the Closing and Early Termination of Hart-Scott-Rodino Waiting Period for License of Microbiome Gastrointestinal Development Programs to Allergan

INDIANAPOLIS, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
February 16, 2017 07:05 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Announces Successful Completion of ABI-H0731 Phase 1a Trial and Upcoming Conference Presentations

INDIANAPOLIS, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
January 09, 2017 08:00 ET | Source: Assembly Biosciences, Inc.

Allergan Enters Into Licensing Agreement with Assembly Biosciences to Obtain Worldwide Rights to Microbiome Gastrointestinal Development Programs

-- Expands Allergan’s Innovative GI Pipeline with ABI-M201 and ABI-M301, Preclinical Compounds Targeting Ulcerative Colitis and Crohn’s Disease, as well as Future Compounds for Irritable Bowel...
November 11, 2016 08:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences to Present Data on ABI-H0731 at AASLD 2016 Liver Meeting

INDIANAPOLIS, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
November 09, 2016 07:05 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Initiates Phase 1 Clinical Program of ABI-H0731 for Treatment of Chronic Hepatitis B Virus Infection

INDIANAPOLIS, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
September 28, 2016 07:00 ET | Source: Assembly Biosciences

Assembly Biosciences Announces Key Additions to Microbiome Team

INDIANAPOLIS, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing novel oral therapeutics for disorders associated with the human...
September 21, 2016 07:30 ET | Source: Assembly Biosciences

Assembly Biosciences Announces Participation in HBV Scientific Meetings in China and South Korea

INDIANAPOLIS, Sept. 21, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus...